Mr. Arbuckle joined Vertex in September 2012. As Vertex’s Executive Vice President and Chief Operating Officer, Mr. Arbuckle oversees Vertex’s global commercial team, which is responsible for the company’s reimbursement and access, sales, marketing, patient support, and market research, as well as Vertex's commercial manufacturing and supply chain functions, and other activities that support the approved use of Vertex’s marketed medicines around the world. Mr. Arbuckle also oversees the Human Resources and Corporate Communications functions.
Mr. Arbuckle has more than 30 years of experience in leading global sales and marketing efforts at biopharmaceutical companies. Prior to joining Vertex, Mr. Arbuckle held multiple commercial leadership roles at Amgen, Inc. As Vice President and General Manager, Oncology Business Unit, he led sales, marketing, patient advocacy and access efforts for Amgen’s portfolio of cancer medicines. He was responsible for sales and marketing efforts for Aranesp® (darbepoetin alfa), Neulasta® (pegfilgrastim) injection and NEUPOGEN®(filgrastim), which accounted for more than $5 billion in sales in 2011, and led the successful launches of XGEVA® (denosumab) injection and Nplate® (romiplostin) injection. Most recently, he served as Vice President and Regional General Manager where he led efforts to expand Amgen's presence in Japan, Asia, the Middle East and Africa.
Prior to these roles, Mr. Arbuckle spent 15 years at GlaxoSmithKline (GSK) plc, where he held sales and marketing roles of increasing responsibility for medicines aimed at treating respiratory, metabolic, musculoskeletal, cardiovascular and other diseases. He joined GSK after earning a degree in pharmacology and physiology from the University of Leeds in the United Kingdom.
Mr. Arbuckle currently serves as a member of Rhythm Pharmaceuticals and ImmunoGen's board of directors, as a national board member of the Cancer Support Community, an international non-profit dedicated to providing support, education and hope to people affected by cancer, and on the Executive Committee and Health Section Governing Board for the Biotechnology Innovation Organization (BIO). He is also co-chair of the BIO Standing Committee on Access & Value.
What is Stuart A. Arbuckle's net worth?
The estimated net worth of Stuart A. Arbuckle is at least $29.98 million as of February 12th, 2024. Mr. Arbuckle owns 75,718 shares of Vertex Pharmaceuticals stock worth more than $29,984,328 as of April 19th. This net worth evaluation does not reflect any other assets that Mr. Arbuckle may own. Additionally, Mr. Arbuckle receives a salary of $2,700,000.00 as COO at Vertex Pharmaceuticals. Learn More about Stuart A. Arbuckle's net worth.
How old is Stuart A. Arbuckle?
Mr. Arbuckle is currently 58 years old. There are 6 older executives and no younger executives at Vertex Pharmaceuticals. The oldest executive at Vertex Pharmaceuticals is Dr. Jeffrey Marc Leiden M.D., Ph.D., Executive Chairman, who is 68 years old. Learn More on Stuart A. Arbuckle's age.
What is Stuart A. Arbuckle's salary?
As the COO of Vertex Pharmaceuticals Incorporated, Mr. Arbuckle earns $2,700,000.00 per year. The highest earning executive at Vertex Pharmaceuticals is Dr. Reshma Kewalramani FASN, M.D., CEO, President & Director, who commands a salary of $5,220,000.00 per year. Learn More on Stuart A. Arbuckle's salary.
How do I contact Stuart A. Arbuckle?
Has Stuart A. Arbuckle been buying or selling shares of Vertex Pharmaceuticals?
Stuart A. Arbuckle has not been actively trading shares of Vertex Pharmaceuticals during the past quarter. Most recently, Stuart A. Arbuckle sold 4,295 shares of the business's stock in a transaction on Monday, February 12th. The shares were sold at an average price of $420.24, for a transaction totalling $1,804,930.80. Following the completion of the sale, the chief operating officer now directly owns 75,718 shares of the company's stock, valued at $31,819,732.32. Learn More on Stuart A. Arbuckle's trading history.
Who are Vertex Pharmaceuticals' active insiders?
Vertex Pharmaceuticals' insider roster includes David Altshuler (EVP), Kristen Ambrose (CAO), Stuart Arbuckle (COO), Sangeeta Bhatia (Director), Jonathan Biller (EVP), Joshua Boger (Director), Carmen Bozic (CMO), Reshma FASN (M.D.), Reshma Kewalramani (CEO), Yuchun Lee (Director), Jeffrey Leiden (Chairman), Joy Liu (SVP), Margaret McGlynn (Director), Michael Parini (EVP), Amit Sachdev (EVP), Bruce Sachs (Director), Bastiano Sanna (EVP), Paul Silva (CAO), Ian Smith (COO), Ourania Tatsis (EVP), and Charles Wagner, Jr. (CFO). Learn More on Vertex Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Vertex Pharmaceuticals?
During the last year, insiders at the pharmaceutical company sold shares 32 times. They sold a total of 115,042 shares worth more than $42,520,712.26. The most recent insider tranaction occured on February, 26th when EVP Ourania Tatsis sold 354 shares worth more than $150,697.80. Insiders at Vertex Pharmaceuticals own 0.2% of the company.
Learn More about insider trades at Vertex Pharmaceuticals. Information on this page was last updated on 2/26/2024.
